- Home
- SKYE vs DSP Comparison
SKYE vs DSP Comparison
Compare SKYE & DSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- DSP
- Stock Information
- Founded
- SKYE 2012
- DSP 1999
- Country
- SKYE United States
- DSP United States
- Employees
- SKYE N/A
- DSP N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- DSP EDP Services
- Sector
- SKYE Health Care
- DSP Technology
- Exchange
- SKYE Nasdaq
- DSP Nasdaq
- Market Cap
- SKYE 172.9M
- DSP 167.4M
- IPO Year
- SKYE N/A
- DSP 2021
- Fundamental
- Price
- SKYE $6.35
- DSP $9.93
- Analyst Decision
- SKYE Strong Buy
- DSP Strong Buy
- Analyst Count
- SKYE 4
- DSP 5
- Target Price
- SKYE $19.25
- DSP $11.60
- AVG Volume (30 Days)
- SKYE 156.3K
- DSP 98.0K
- Earning Date
- SKYE 08-09-2024
- DSP 08-12-2024
- Dividend Yield
- SKYE N/A
- DSP N/A
- EPS Growth
- SKYE N/A
- DSP N/A
- EPS
- SKYE N/A
- DSP N/A
- Revenue
- SKYE N/A
- DSP $243,250,000.00
- Revenue This Year
- SKYE N/A
- DSP $19.71
- Revenue Next Year
- SKYE N/A
- DSP $12.84
- P/E Ratio
- SKYE N/A
- DSP N/A
- Revenue Growth
- SKYE N/A
- DSP 20.25
- 52 Week Low
- SKYE $1.44
- DSP $4.98
- 52 Week High
- SKYE $19.41
- DSP $12.36
- Technical
- Relative Strength Index (RSI)
- SKYE 55.48
- DSP 40.21
- Support Level
- SKYE $5.71
- DSP $10.27
- Resistance Level
- SKYE $6.69
- DSP $11.41
- Average True Range (ATR)
- SKYE 0.71
- DSP 0.40
- MACD
- SKYE 0.11
- DSP -0.08
- Stochastic Oscillator
- SKYE 59.12
- DSP 1.33
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.